A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for
primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA
nephropathy.